ClinicalTrials.gg
Active, not recruitingNCT06447779Updated Oct 19, 2026

Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older

A Phase 3 interventional study of Recombinant Zoster Vaccine (CHO Cell) and NaCl solution Placebo in Herpes Zoster, sponsored by MAXVAX Biotechnology Limited Liability Company. Active, not recruiting at 4 sites in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by MAXVAX Biotechnology Limited Liability Company · Phase 3, Interventional, and Prevention

Updated Oct 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25,000
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Herpes Zoster with a site in China — 26 open to participants now, 31 under way, 3 of them phase 3. Herpes Zoster · China.

Planned enrollment
2nd of 45
25,000 · median 519
Started
2024
with 8 others
Phase 3
6 of 51
1 open now
Primary completion
2026-03
later than 8 of 30 live
Registered
21st of 51
by date
Lead sponsor
5 of 51
MAXVAX Biotechnology Limited Liability Company

Among the 51 studies in Herpes Zoster with a site in China, this one is the 2nd largest by planned enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2024, is one of 6 in phase 3, reaches primary completion later than 8 of the 30 other live ones, and was the 21st registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

26 of the 51 studies in Herpes Zoster with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Herpes Zoster with a site in China, or all of them as a file.
02

Study summary

The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.

Read the detailed description

A total of 25000 adults aged 40 years and older will be enrolled, stratified into 40-49, 50-59, 60-69 and ≥70 years of age. All subjects will randomly receive investigational vaccine or placebo at a ratio of 1:1. Efficacy and safety will be assessed in all subjects, while immunogenicity will be assessed in a subset of 1250 subjests in a selected trial site.

03

Conditions studied

  • Herpes Zoster

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A male or famale permanent resident aged 40 years and older at enrollment, with valid identity;
  2. Subjects voluntarily agree to participate in the study and signed an ;
  3. Be able to understand clinical trials, participate in all scheduled visits and comply with the protocol requirements(e.g. completion of the diary cards/questionnaires, return for follow-up visits, have regular contact to allow evaluation during the study);
  4. Women of plan to aviod pregnancy and are willing to use effcetive (e.g. oral contraceptive pills, injectable progestogen, percutaneous contraceptive patches, implants of levonorgestrel, intrauterine device, female and male sterilization or abstinence) within 12 months after the last vaccination, and the uses of the rhythm method alone, withdrawal alone, and emergency contraception, are not acceptable.

Exclusion criteria

Exclusion Criteria:

  1. Axillary temperature>37.0℃;
  2. Current or history of herpes zoster;
  3. Previous vaccination against varicella or herpes zoster (either registered product or participation in a previous vaccine study);
  4. Pregnant (urine pregnancy test was positive) or lactating female;
  5. Receipt of within 28 days, or any other vaccine within 14 days prior to vaccination;
  6. Receipt of immunoglobulin or intravenous immunoglobulin during 3 months before vaccination to 1 month post the last vaccination;
  7. Acute diseases or acute exacerbation of chronic disease within 3 days before vaccination;
  8. Receipt of antipyretic, analgesic and allergy drugs within 3 days before vaccination, except enteric-coated aspirin for cardiovascular diseases prevention;
  9. A known allergy to any components of the study vaccine, or history of severe allergy (e.g. Anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, Arthus reaction, severe urticaria) to any previous vaccination;
  10. Allergy to aminoglycoside antibiotics;
  11. History of convulsions, epilepsy, encephalopathy (e.g. congenital brain dysplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarction, brain infection disease, nerve tissue damage caused by chemical drug poisoning), mental illness and family history, and other serious neurological diseases;
  12. Asplenia or functional asplenia, or splenectomy caused by any condition;
  13. Primary or secondary impairment of immune function, diagnosed congenital or acquired immunodeficiency, (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease or other diseases;
  14. Receipt of therapy (e.g. long-term use of systemic ≥14 days, dose ≥2mg/kg/day or ≥20mg/day prednisone or equivalent dose) during 6 months before vaccination to 1 minth post the last vaccination, but inhaled, nasal spray, intra-articular, eyedrops, ointment and other topical steroids are acceptable;
  15. Receipt of long-acting immune-modifying drugs (e.g. Infliximab) within 6 months before vaccination or during the study period;
  16. Severe chronic disease, including but not limited to, severe cardiovascular disease(e.g. Pulmonary heart disease, Pulmonary Edema), severe liver or kidney disease, or diabetes with complication;
  17. History of thrombocytopenia or other coagulation disorders, which may cause intramuscular injection ;
  18. Abnormal and uncontrlled blood pressure during physical examination before vaccination (for subjects aged 40-59: systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg; for subjects aged ≥60, systolic pressure ≥ 150 mmHg and/or diastolic pressure ≥ 100 mmHg);
  19. History of drug abuse (narcotic drugs, psychotropic drugs);
  20. Current skin infections, in the opinion of the investigator, might interfere with the efficacy evaluation;
  21. Current or history of malignant tumors, except papillary thyroid carcinoma;
  22. Receipt of products (drugs or vaccines) within 6 months before vaccination;
  23. Planned participation in another clinical study during the study period;
  24. Any condition that, in the opinion the investigator, may affect the safety of the subject or the evaluation of the study results.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25,000 participants (estimated)

Study arms

  • Experimental
    Vaccine Group

    Subjects will receive Recombinant Zoster Vaccine (CHO cell) according to a 0, 2-month schedule

    Biological: Recombinant Zoster Vaccine (CHO Cell)

  • Placebo comparator
    Placebo Group

    Subjects will receive NaCl solution placebo according to a 0, 2-month schedule

    Biological: NaCl solution Placebo

Interventions

  • 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection

  • BiologicalNaCl solution Placebo

    0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection

06

What researchers measure

Primary outcomes

  1. Incidence of confirmed Herpes Zoster(HZ) Cases per person years in subjects aged 40 years and older

    A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the Endpoint Adjudication Committee (EAC), consisting of physicians with HZ expertise.

    Time frame: 30 days after the last vaccination

Secondary outcomes

  1. Incidence of confirmed Herpes Zoster(HZ) Cases per person years in different age group.

    All subjects will be stratified into 40-49 years, 50-59 years, 60-69 years and ≥70 years of age.

    Time frame: 30 days after the last vaccination

  2. Incidence of any and severe Postherpetic Neuralgia (PHN) cases per person years in subjects aged 40 years and older, 40-49years , 50-59 years , 60-69 years and ≥70 years , with confirmed HZ.

    PHN of any severity was defined as 0 and greater on the Zoster Brief Pain Inventory(ZBPI) questionnaire, while severe PHN rated as 3 and greater on the ZBPI questionnaire.

    Time frame: 30 days after the last vaccination

  3. Geometric Mean Concentration(GMC) of anti-gE antibody and anti-VZV antibody in immunogenicity subset

    Measured by ELISA

    Time frame: At 1, 12, 24 and 36 months after the last vaccination

  4. Seropositivity rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset

    The seropositivity rate is defined as the percentage of subjects whose antibody concentration is greater than or equal to the cut-off value.

    Time frame: At 1, 12, 24 and 36 months after the last vaccination

  5. Seroresponse rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset

    The seroresponse rate is defined as the percentage of subjects who have at least a: 4-fold increase in the antibody concentration as compared to the pre vaccination antibody concentration, for subjects who are seropositive at baseline, OR, 4-fold increase in the antibody concentration as compared to the antibody concentration cut-off value for seropositivity, for subjects who are seronegative at baseline.

    Time frame: 30 days after the last vaccination

  6. Geometric Mean Fold Rise (GMFR) of anti-gE antibody and anti-VZV antibody in immunogenicity subset

    The antibody concentration at evaluted time points compared with that at baseline.

    Time frame: At 1, 12, 24 and 36 months after the last vaccination

  7. Four-fold increase rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset

    The antibody concentration 30 days after the last vaccination compared with that at baseline.

    Time frame: 30 days after the last vaccination

  8. Cell-Mediated Immunity (CMI) response

    CMI response is defined as the frequency of CD4+ T cells producing at least 2 activation markers (IFN-γ, IL-2, TNF-α and/or CD40L) upon in vitro stimulation by gE peptide pools.

    Time frame: 30 days after the last vaccination

  9. Vaccine Response Rate (VRR)

    VRR is defined as the percentage of subjects with at least a 2-fold increase as compared to the Cut-off, for subjects with pre-vaccination T-cell frequencies\<Cut-off, OR, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies for subjects with pre-vaccination T-cell frequencies ≥Cut-off.

    Time frame: 30 days after the last vaccination

  10. Number of Participants With solicited local symptoms

    Assessed solicited local symptoms were pain, Induration, swelling, redness, pruritus, rash, and cellulitis.

    Time frame: Within 7 days after each vaccination

  11. Number of Participants With solicited general symptoms.

    Assessed solicited general symptoms were fever \[defined as axillary equal to or above 37.3 degrees Celsius (°C)\], diarrhoea, anorexia, vomiting, nausea, abdominal pain, myalgia, arthralgia, headache, syncope, new convulsions, cough, pruritus (non-vaccination site), skin and mucous membrane abnormalities, acute allergic reactions, fatigue, pain (non-vaccination site), chills.

    Time frame: Within 7 days after each dose

  12. Number of Participants With unsolicited adverse events

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: During 30 days after each vaccination

  13. Number of Participants With Serious Adverse Events

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: From the day of first vaccination up to 12 months after last vaccination

  14. Number of Participants With potential Immune Mediated Disorders

    pIMDs are a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From the day of first vaccination up to 12 months after last vaccination

07

Study locations

4 sites
  • Hebei Provincial Center for Disease Control and Prevention
    Shijiazhuang, Hebei 050021, China
  • Henan Center for Diseases Control and Prevention
    Zhengzhou, Henan 450016, China
  • Hubei Provincial Center for Disease Control and Prevention
    Wuhan, Hubei 430070, China
  • Yunnan Center For Disease Control and Prevention
    Kunming, Yunnan 650022, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Mar 2026, 20 months.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 20 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Sep 2025 → Mar 2026 and completion Sep 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2024
First posted
Jun 7, 2024
StartActual
Jul 13, 2024
Primary completionActual
Mar 29, 2026was Sep 2025
CompletionEst.
Nov 2027was Sep 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2025→Mar 29, 2026 (actual)
Oct 19, 2026
Study completion
Sep 2027→Nov 2027
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Sep 2025→Mar 29, 2026 (now actual)
    Study completion Sep 2027→Nov 2027
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06447779
Lead sponsor
MAXVAX Biotechnology Limited Liability Company
Responsible party
Sponsor
First posted
Jun 7, 2024
Start date
Jul 13, 2024
Primary completion
Mar 29, 2026
Completion
Nov 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Wang Yanxia
principal investigator · Henan Center for Disease Control and Prevention

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHO cell

Start the discussion